Pipeline

Clinical Pipeline


Shattuck’s Platform Combines Checkpoint Inhibition with TNF Costimulation

To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 400 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The two clinical-stage ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1 and CD47) while simultaneously stimulating T cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead clinical-stage product candidate, SL-172154 (SIRPα-Fc-CD40L), is in two Phase 1 clinical trials, the first for patients with platinum-resistant ovarian cancer (NCT04406623) and the second for patients with AML and HR-MDS (NCT05275439). Shattuck’s second clinical-stage product candidate, SL-279252 (PD1-Fc-OX40L), is in a Phase 1 trial in patients with solid tumors and lymphoma (NCT03894618).

PlatformProgramDomain 1Domain 2IndicationsDiscoveryPreclinicalPhase 1Phase 2Phase 3
Clinical-Stage Pipeline
ARCSL-172154SIRPαCD40LOvarian Cancer(1)
ARCSL-172154SIRPαCD40LCSCC and HNSCC(2)
ARCSL-172154AML and HR-MDS(3)
ARCSL-279252PD-1OX40LAdvanced Solid Tumors and Lymphoma
Select Preclinical-Stage Pipeline
ARCSL-9258TIGITLIGHTOncology
ARCSL-279137PD-14-1BBLOncology
ARCMultipleUndisclosedUndisclosedAutoimmune
GADLENMultipleγδ TCRTumor AntigenOncology
Drug Indication Stage
SL-172154 Ovarian Cancer(1) Phase 1
SL-172154 CSCC and HNSCC(2) Phase 1
SL-172154 AML and HR-MDS(3) Phase 1
SL-279252 Advanced Solid Tumors and Lymphoma Phase 1
SL-9258 Oncology Preclinical
SL-279137 Oncology Preclinical
Multiple Autoimmune Preclinical
Multiple Oncology Preclinical

(1) Ovarian cancer in combination with Liposomal Doxorubicin
(2) Cutaneous Squamous Cell Carcinoma (CSCC) and Head and Neck Squamous Cell Carcinoma (HNSCC) via intratumoral injection
(3) Acute Myeloid Leukemia (AML) in combination with Azacitidine + Venetoclax and Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant AML in combination with Azacitidine